A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

NCT02541604 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
87
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to terminate because limited investigational agent activity was observed.

Conditions

Interventions

Sponsor

Hoffmann-La Roche